These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 29787289)
1. Trends of LSD1 inhibitors in viral infections. Zwergel C; Stazi G; Mai A; Valente S Future Med Chem; 2018 May; 10(10):1133-1136. PubMed ID: 29787289 [No Abstract] [Full Text] [Related]
2. Inhibitors of enzymes catalyzing modifications to histone lysine residues: structure, function and activity. Lillico R; Stesco N; Khorshid Amhad T; Cortes C; Namaka MP; Lakowski TM Future Med Chem; 2016 May; 8(8):879-97. PubMed ID: 27173004 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of the histone demethylase LSD1 blocks alpha-herpesvirus lytic replication and reactivation from latency. Liang Y; Vogel JL; Narayanan A; Peng H; Kristie TM Nat Med; 2009 Nov; 15(11):1312-7. PubMed ID: 19855399 [TBL] [Abstract][Full Text] [Related]
4. Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors. Kakizawa T; Ota Y; Itoh Y; Suzuki T Bioorg Med Chem Lett; 2018 Jan; 28(2):167-169. PubMed ID: 29198865 [TBL] [Abstract][Full Text] [Related]
5. Expression, Purification, and Biochemical Analysis of the LSD1/KDM1A Histone Demethylase. Laurent B; Shi Y Methods Enzymol; 2016; 573():241-59. PubMed ID: 27372756 [TBL] [Abstract][Full Text] [Related]
6. Histone H3 peptide based LSD1-selective inhibitors. Kakizawa T; Ota Y; Itoh Y; Tsumoto H; Suzuki T Bioorg Med Chem Lett; 2015 May; 25(9):1925-8. PubMed ID: 25827526 [TBL] [Abstract][Full Text] [Related]
7. Histone Lysine Demethylase Inhibitors. Jambhekar A; Anastas JN; Shi Y Cold Spring Harb Perspect Med; 2017 Jan; 7(1):. PubMed ID: 28049654 [TBL] [Abstract][Full Text] [Related]
8. Histone demethylase LSD1 restricts influenza A virus infection by erasing IFITM3-K88 monomethylation. Shan J; Zhao B; Shan Z; Nie J; Deng R; Xiong R; Tsun A; Pan W; Zhao H; Chen L; Jin Y; Qian Z; Lui K; Liang R; Li D; Sun B; Lavillette D; Xu K; Li B PLoS Pathog; 2017 Dec; 13(12):e1006773. PubMed ID: 29281729 [TBL] [Abstract][Full Text] [Related]
9. Fluorinated tranylcypromine analogues as inhibitors of lysine-specific demethylase 1 (LSD1, KDM1A). Borrello MT; Schinor B; Bartels K; Benelkebir H; Pereira S; Al-Jamal WT; Douglas L; Duriez PJ; Packham G; Haufe G; Ganesan A Bioorg Med Chem Lett; 2017 May; 27(10):2099-2101. PubMed ID: 28390942 [TBL] [Abstract][Full Text] [Related]
10. Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors. Nie Z; Shi L; Lai C; Severin C; Xu J; Del Rosario JR; Stansfield RK; Cho RW; Kanouni T; Veal JM; Stafford JA; Chen YK Bioorg Med Chem Lett; 2019 Jan; 29(1):103-106. PubMed ID: 30409536 [TBL] [Abstract][Full Text] [Related]
11. LSD1 inhibitors: a patent review (2010-2015). Stazi G; Zwergel C; Valente S; Mai A Expert Opin Ther Pat; 2016 May; 26(5):565-80. PubMed ID: 27019002 [TBL] [Abstract][Full Text] [Related]
12. Identification of selective and reversible LSD1 inhibitors with anti-metastasis activity by high-throughput docking. Li L; Li R; Wang Y Bioorg Med Chem Lett; 2019 Feb; 29(4):544-548. PubMed ID: 30611617 [TBL] [Abstract][Full Text] [Related]
14. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. Willmann D; Lim S; Wetzel S; Metzger E; Jandausch A; Wilk W; Jung M; Forne I; Imhof A; Janzer A; Kirfel J; Waldmann H; Schüle R; Buettner R Int J Cancer; 2012 Dec; 131(11):2704-9. PubMed ID: 22447389 [TBL] [Abstract][Full Text] [Related]
15. Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity. Schmitt ML; Hauser AT; Carlino L; Pippel M; Schulz-Fincke J; Metzger E; Willmann D; Yiu T; Barton M; Schüle R; Sippl W; Jung M J Med Chem; 2013 Sep; 56(18):7334-42. PubMed ID: 24007511 [TBL] [Abstract][Full Text] [Related]
16. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer. Hosseini A; Minucci S Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367 [TBL] [Abstract][Full Text] [Related]
17. Development and Structural Evaluation of N-Alkylated trans-2-Phenylcyclopropylamine-Based LSD1 Inhibitors. Niwa H; Sato S; Handa N; Sengoku T; Umehara T; Yokoyama S ChemMedChem; 2020 May; 15(9):787-793. PubMed ID: 32166890 [TBL] [Abstract][Full Text] [Related]
18. Identification of cell-active lysine specific demethylase 1-selective inhibitors. Ueda R; Suzuki T; Mino K; Tsumoto H; Nakagawa H; Hasegawa M; Sasaki R; Mizukami T; Miyata N J Am Chem Soc; 2009 Dec; 131(48):17536-7. PubMed ID: 19950987 [TBL] [Abstract][Full Text] [Related]
19. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors. Spannhoff A; Hauser AT; Heinke R; Sippl W; Jung M ChemMedChem; 2009 Oct; 4(10):1568-82. PubMed ID: 19739196 [TBL] [Abstract][Full Text] [Related]
20. Targeting LSD1 in cancer: Molecular elucidation and recent advances. Cai W; Xiao C; Fan T; Deng Z; Wang D; Liu Y; Li C; He J Cancer Lett; 2024 Aug; 598():217093. PubMed ID: 38969160 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]